USA > Switzerland based Novartis is set to acquire USA based AveXis Inc. for $8.7 billion

Novartis logo To transform care in SMA and expand its position as a gene therapy and Neuroscience leader, Novartis is set to acquire AveXis Inc. for $8.7 billion. AVXS-101, AveXis lead product candidate, has the potential to be the first ever one time gene replacement therapy for spinal muscular atrophy (SMA). SMA is a disease that results in either early death or More …